Latest Data of InnoCare's Oncology Pipelines Presented at the 65th Annual Meeting of ASH | Region

BEIJING--(BUSINESS WIRE)--Dec 10, 2023--

Related Keywords

China ,Guangzhou ,Guangdong ,Tianjin ,Hong Kong ,Nanjing ,Jiangsu ,Zhongshan ,Anhui ,Beijing ,Shanghai ,Peking ,United States ,American ,Chinese ,Chunhua Lu ,Innocare Pharma ,Peng Liu ,Shuhua Yi ,Huilai Zhang ,American Society Of Hematology ,Chinese Academy Of Medical Sciences ,Fudan University ,Tianjin Medical University Cancer Institute ,Union Medical College ,Care Pharma ,American Society ,Untreated Mantle Cell Lymphoma ,Preliminary Analysis ,Mutation Spectrum ,Mutation Profiling ,Treatment Responses ,Abstract Number ,Professor Huilai Zhang ,Efficacy Data ,Refractoryb Cell Malignancies Treated ,Next Generation ,Chinese Academy ,Medical Sciences ,Peking Union Medical ,Orelabrutinib Combined ,Rituximab As First Line Treatment ,Marginal Zone Lymphoma ,Professor Peng Liu ,Zhongshan Hospital ,Business Wire ,Region ,